Colorectal cancer is the second leading cause of cancer-related death in Australia. This can be attributed to the silent nature of the disease, not causing symptoms until tumours are well established. The Australian Government is all too aware of this, having created the National Bowel Cancer Screening Program with the goal of early detection to
Read More
Colorectal cancer is the third most commonly occurring cancer in men, and the second in women. Yet every year 130 million people around the world between the ages of 50-74 remain unscreened. Rhythm Biosciences (ASX: RHY) are not complacent with that number and are working on an innovative solution to aid diagnosis of this major
Read More
We recently had a one-on-one meeting with Mr. Glenn Gilbert, CEO of Rhythm Biosciences (ASX: RHY). As we do not cover the stock, the main purpose of this call was to get an initial understanding of the Company’s business model as we develop our knowledge on the stock. RHY is a cancer diagnostics technology developer,
Read More
Aussie medtech company Rhythm Biosciences (ASX: RHY) is set to improve the screening process of colorectal cancer with manufacturing of their ColoSTAT testing kit to commence shortly after having appointed Biotem Limited as their new global manufacturer. Colorectal cancer is the third biggest cause for cancer deaths globally where current screening processes tend only to
Read More